Browse studies

Find your next paid study

1 recruiting study matching your filters

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements

This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 1…

Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement

Taiho Oncology, Inc.NCT05727176